Processing of personal data under Law n° 1.565 of 3 December 2024.
Law n° 1.565 dated December 3rd 2024
Dear user,
In accordance with our obligations under the Law n° 1.565 dated December 3rd 2024 (the Law), we give you notice that your personal data are handled (“processed”) by Lena Corporation S.A.M., with registered office at 74 Boulevard d’Italie - 98000 MC Monaco.
Details of that processing are set out below.
The Data Controller for your personal data, answerable to you for the lawful and proper use of your personal data, is Lena Corporation S.A.M., with registered office at 74 Boulevard d’Italie - 98000 MC Monaco – contact details privacy@lenagroup.net, in the person of its duly empowered manager.
You can address queries or requests to the Data Controller using the contact details below.
The purposes for which your personal data are collected and processed are set out below, with the legal basis for each:
| Purpose | Data processed | Legal basis |
|---|---|---|
| Your participation to the event 5th European Bronchiectasis Workshop in union with the event 9th International Forum on Respiratory Tract Infections to be held London, 8-11 February 2027 (in the following the Event). |
Personal data identifying you:
|
Your express written consent to the processing of your personal data. |
Your personal data will be processed lawfully and in accordance with the principles of fair play and transparency, with or without the help of electronic tools, in such a way as to safeguard their accuracy, integrity and confidentiality at all times.
Your personal data are processed and stored in Ireland and in the Netherlands.
In accordance with the Law, your personal data will be kept for no longer than the time needed for the purposes for which they are processed.
The length of time for which your personal data continue to be processed is determined as follows: your personal data will be processed from the time you sign up to participating in the Event and will be kept for the length of time needed for us to discharge our legal obligations, which in this case is 10 year after the end of the Event.
The start date of the processing will be the date when you register and complete the attached form.
Providing your personal data is a necessary condition of taking part in the Event and your access to all the services connected with it, such as travel or board and lodging at the establishments selected by the organizer of the Event.
Provision of your personal data is optional, but if they are not processed this will hinder the proper performance of the above activities by Lena Corporation S.A.M..
Your personal data collected are kept at Microsoft Cloud (Netherland and Ireland); they are processed only by specifically authorized staff and only in the course of their duties.
Within the purposes indicated in point 2 of this privacy notice, your personal data may be communicated to:
In particular, your personal data may be communicated to subjects operating in the following sectors:
Only the category of recipients is specified, as it is subject to frequent updates and revisions. The updated list of recipients may be requested by contacting the Data Controller through the channels indicated in point 1 of this privacy notice.
Your personal data will be sent to other countries in the European Union.
While guaranteeing that your personal data collected will be processed in the most proper and transparent manner possible, we give you notice that you can exercise the following rights under the Law (article 11):
You can exercise these rights by sending an explicit written request to the Data Controller in one of the following ways:
Your personal data will not be disseminated, nor subject to profiling or any other fully automated decision-making process.
I hereby consent to be photographed and/or filmed during the Event, by the press and communications media present at the Event and authorize them to reproduce and distribute, directly or through third parties, on a non-exclusive basis and worldwide, my image and voice, as well as to use these photographs or videos in part or in full, in any form and on any media, including for commercial purposes.
The right to use photographs and videos depicting me includes, in particular:
The use of my image must in no way invade my privacy, or more generally harm me or cause me any harm.
I further acknowledge that I am not bound by any exclusive contract regarding the use of my image or name.
This authorization to use my image is granted free of charge.
Any questions or requests may be addressed to LENA CORPORATION SAM – 74 Bd d’Italie – 98000 Monaco, email: privacy@lenagroup.net.
Michal Shteinberg is heading the bronchiectasis and adult CF service in the Pulmonology institute and CF center, Carmel medical center, Haifa, Israel. She is a Clinical Assistant Professor in the Faculty of medicine at the Technion, Israel Institute of Technology. Her main research interests are bronchiectasis and its overlap with other airway diseases, and adult CF.
Head of the Pulmonology Service at Hospital Clínic de Barcelona and accredited researcher in the IDIBAPS group Inflammation and Repair in Respiratory Diseases. His work focuses on airway infection, inflammation and bronchiectasis, including frequent-exacerbator phenotypes in the EMBARC registry.
He coordinates educational programmes on bronchiectasis at Hospital Clínic and publishes widely on mucins, inhaled therapies and treatable traits in chronic airway disease.
Natalie Lorent works as a consultant in Respiratory Medicine/Clinical Infectiology at the University Hospital Leuven where since 2015 she coordinates the care for adults with respiratory infections, bronchiectasis (CF and non-CF) and primary ciliary dyskinesia. She is involved in clinical and translational research in bronchiectasis and mycobacterial infections.
She is founder and president of the national NTM Consilium, a clinical advisory board and basis of a national registry; she chairs the European NTM research network (NTMnet) and the Belgian MDRTB expert group. She has been involved in EMBARC since the start. Natalie is also assistant professor at KU Leuven.
Felix C. Ringshausen is a board-certified physician for respiratory medicine and infectious diseases and head of the Adult Bronchiectasis and Cystic Fibrosis Service at the Hannover Medical School, Germany. In addition, he is principal investigator of the German Center for Lung Research (DZL).
His research interests are focused on European multidisciplinary networks and multicenter initiatives in order to promote clinically orientated research and improve patient care in the field of rare, neglected and under-researched aspects of respiratory infections like bronchiectasis, nontuberculous mycobacteria, respiratory viruses and adult cystic fibrosis.
Professor of Respiratory Medicine, Humanitas University, Milan, Italy. Consultant, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan.
Co-chair of the European Bronchiectasis Network (EMBARC). Chair of IRIDE, the Italian Registry of adult bronchiectasis. Chair of the Italian Registry on Non-Tuberculous Mycobacteria (IRENE).
Professor Michael Loebinger is Professor of Practice at Imperial College London and Director of the Lung Division and Deputy Medical Director at Royal Brompton Hospital. He co-chaired the British Thoracic Society bronchiectasis guidelines and co-wrote the BTS Non-Tuberculous Mycobacteria and European Respiratory Society bronchiectasis guidelines.
He is a founding member of the UK and European clinical and research bronchiectasis and NTM networks and has authored over 200 publications. He has helped design and lead multiple global clinical trials in bronchiectasis and NTM and was chief investigator for the first mRNA trials in primary ciliary dyskinesia.
Charles Haworth is a Respiratory Consultant working within the Cambridge Centre for Lung Infection at Royal Papworth Hospital where he specialises in treating adults with bronchiectasis, non-tuberculous mycobacterial (NTM) infections and cystic fibrosis.
He co-authored the British Thoracic Society Bronchiectasis clinical guidelines published in 2017 and the European Respiratory Society Bronchiectasis clinical guidelines published in 2019.
He was also senior author of the International Cystic Fibrosis NTM guidelines published in 2015 and first author of the British Thoracic Society NTM guidelines published in 2017.
From 2018 to 2021, he was a founding and executive committee member of the UK Cystic Fibrosis Medical Association.
In June 2024 he was invited to join the Board of the European Cystic Fibrosis Society.
Rhodes Chair of Experimental Therapeutics and Clinical Pharmacology, University of Oxford.
Chief Editor of the European Respiratory Journal.
Chair of the European Bronchiectasis Network (EMBARC).
Chair of the Standards of Care Committee of the British Thoracic Society.
